Latest Revenue Growth News

CSL Limited reported solid FY25 financials with 5% revenue growth and announced a strategic transformation including a $500 million annual cost saving target and plans to spin off its vaccine business, CSL Seqirus, as a separate ASX-listed entity.

CSL Limited reported robust FY25 results alongside a sweeping strategic overhaul, including a major cost-saving program and plans to spin off its vaccine unit CSL Seqirus as a standalone ASX-listed company.

Reliance Worldwide Corporation reported a solid 5.5% revenue increase and a 13.5% rise in net profit for FY25, driven by the full-year impact of its Holman Industries acquisition and strategic capital returns.

HMC Capital Limited reported a record FY25 profit of $265.2 million, driven by strategic acquisitions and growth in digital infrastructure and energy transition sectors. The company also declared a consistent dividend and strengthened its balance sheet with an increased undrawn debt facility.

Simonds Group reported a stable $665.6 million revenue for FY25, with normalised net profit after tax surging 90% to $5.7 million, driven by the acquisition of Dennis Family Homes and improved margins.

Simonds Group Limited reported steady revenue of $665.6 million for FY2025, alongside a modest net profit of $1.015 million, as it completed the strategic acquisition of Dennis Family Homes. The company is focused on integrating the acquisition and driving growth amid a recovering housing market.

ReNerve Limited has achieved a key milestone with its first sale and clinical use of a deep dermal tissue product in the US, broadening its surgical applications beyond nerve repair. This move complements its existing nerve repair portfolio and sets the stage for further product launches later this year.

Rhythm Biosciences has announced a $3.75 million placement to accelerate the commercial launch of its ColoSTAT® cancer detection test and expand its geneType™ product suite into key markets. The capital raise includes director participation and attaching options, pending shareholder approval.

Adrad Holdings reported an 8.9% rise in FY25 sales revenue to $153.1 million despite a slight dip in EBITDA, while declaring a fully franked dividend and outlining strategic initiatives for FY26.

Adrad Holdings reported solid FY25 results with revenue climbing 8.9% to $153.1 million, despite a slight dip in EBITDA due to cost pressures. The company boosted its dividend by 18%, reflecting confidence in future growth.

Amaero Ltd reported a 470% revenue surge to $3.8 million for FY2025, driven by expanded production capacity and exclusive supply deals, while continuing to invest heavily in infrastructure and operations, resulting in a $24.4 million loss.

Audinate reported a 33% revenue decline in FY25 due to OEM inventory adjustments but boosted gross margins to 82.1% through a software shift and completed the strategic Iris acquisition, setting the stage for growth in FY26.